Ribaxamase is an investigational oral recombinant beta lactamase enzyme that binds with and degrades intravenous (IV) beta-lactam antibiotics that are excreted into the intestines, thus potentially protecting the gut from opportunistic enteric infections without compromising antibiotic therapy. It is proposed for co-administration with certain intravenous beta-lactam antibiotics to prevent Clostridium difficile infection and antibiotic-associated diarrhea.
If you have a Hayes login, click here to view the full report on the Knowledge Center.